NIH R01 Clinical Trial Required Parent NOFO (PA-25-305): 2026/2027 Guide

NIH R01 Clinical Trial Required Parent NOFO (PA-25-305): 2026/2027 Guide

For teams planning large-scale translational or interventional studies in 2026 and 2027, PA-25-305 is the NIH parent pathway to use when the proposal must include a clinical trial. This is the parent notice for R01 Research Project Grants with clinical trial required, and it supports projects aligned to one or more participating NIH Institutes and Centers.

This is not a thematic, niche funding call. It is a broad NIH instrument that can be used across disciplines, from behavioral interventions and imaging trials to mechanistic intervention studies in medicine or human biology. In practice, it is most useful as a “route” for investigators who already have a clinical question and need the NIH R01 framework with clinical trial compliance requirements.

Key details

The source page confirms the NOFO is a parent announcement and was updated for the current NIH policy context. The table on NIH’s page includes recurring NIH standard due dates, so this one stays active as an anchor in planning until the expiry, while individual cycles repeat.

What this opportunity is (and is not)

PA-25-305 is designed for projects that require a clinical trial, not purely non-trial R01s.

What it is

• A parent funding opportunity for R01 applications with clinical trials.
• A recurring, NIH-wide mechanism with participation from multiple Institutes and Centers.
• A route for projects across mission-aligned biomedical and health domains.
• A fit for teams that need NIH standards for human-subject, clinical-trial, and review compliance embedded in the process.

What it is not

• It does not guarantee a fixed total award amount.
• It is not the best fit for non-clinical-trial research questions.
• It is not a fast, non-compliance-friendly process; page and form adherence is strict.
• It is not exempt from NIH-wide and IC-specific review expectations.

The most important interpretation from the NOFO: your proposal must propose at least one clinical trial as defined by NIH and assigned/linked to one or more participating ICs. NIH explicitly states that mechanistic trials are also eligible when they meet the NIH clinical trial definition.

Why this is relevant for 2026/2027 planning

Because this is a parent notice with recurring cycles, your planning should be continuous, not single-shot. The due-date table in the NOFO lists cycles that line up with 2026 and 2027 submission patterns. For example, key dates include June 5 and July 5 in 2026, then February 5/March 5 and June 5/July 5 in 2027. If your study protocol is not ready by one cycle, it may be feasible to target the next available cycle with the same mechanism.

From a strategic perspective, this means your team should:

1. Define a stable clinical trial concept early.
2. Decide which NIH Institute and Center(s) are most appropriate.
3. Build registration and pre-submission compliance milestones backward from an upcoming due date.

The page also explicitly lists “expiration date January 8, 2028,” so 2026/2027 candidates can still rely on this as a practical planning and application base for the year ahead.

How PA-25-305 is structured

The NOFO is structured by the standard NIH Part I/Part II format and includes several sections that matter most for applicants.

Mechanism and project constraints

• Activity: R01.
• Clinical trial: required.
• Project period: up to 5 years.
• Budget: no stated NOFO cap; budgets must be realistic and fit project needs.
• Eligibility includes broad organizational categories: universities, nonprofits (501(c)(3) and non-501(c)(3)), small businesses, for-profit organizations, governments, and foreign entities.
• Cost sharing is not required.

Application types

New, Renewal, Resubmission, and Revision are accepted where allowed by the NOFO text. Duplicate or overlapping applications simultaneously under review are not accepted under NIH policy.

Submission model

You cannot submit by mail or paper.

You must submit electronically via one of the allowed routes:

• ASSIST
• Grants.gov Workspace
• an institutional system-to-system solution (S2S)

NIH also gives explicit instructions around time: all applications are due at 5:00 PM local time of the applicant organization.

Eligibility and scope in practical terms

Because this is a parent NOFO, there are two layers of fit:

1. Mechanism fit: Is your proposal genuinely clinical-trial-centered?
2. IC fit: Is the topic aligned to one or more participating NIH ICs and their stated missions?

Mechanism fit checklist

• Does your protocol include a prospective assignment of human subjects to interventions and outcomes?
• Are you defining and measuring outcomes in a way that supports NIH trial review (methodology, risk/benefit, retention strategy, etc.)?
• If your study is mechanistic, does it still satisfy NIH’s clinical trial definition and reporting expectations?

Organizational fit

The NOFO’s organization list is very broad, including institutions, nonprofits, governments, for-profits, and foreign organizations. This means teams should mostly ask:

• Is your org registered in the required systems?
• Can your sponsor/PI produce a compliant NIH submission package?
• Do you have the infrastructure to run clinical studies with trial governance and ethics oversight?

People and roles

All PD(s)/PI(s) must have an eRA Commons account and submit through the required systems. The NOFO flags timing issues repeatedly: registrations can take weeks, and incomplete registrations can delay or invalidate submission. Institutions should start SAM/eRA/Grants.gov readiness early, even if they have done this before.

Application process, step by step

1) Choose the right cycle and IC route

PA-25-305 is broad at mechanism level but not generic in scientific acceptance. Start by identifying the right IC(s) using NIH guidance pages linked in the NOFO and confirm programmatic interests.

Practical tactic:

• For each target IC, map your primary specific aims and secondary outcomes to a clear IC mission phrase.
• Keep one primary IC route per version of your proposal for submission logistics.
• If you have a truly cross-cutting design, still keep a primary lead IC in mind and document why secondary ICs are interested.

2) Build trial-defensible protocol architecture early

Because clinical trial compliance is mandatory, build these elements before writing narrative:

• Human subjects approach and inclusion strategy.
• Data monitoring and safety plan.
• Retention/enrollment assumptions with contingency (critical for review).
• Randomization/intervention logic (if applicable).
• Data-management and sharing plan (required in scope from NIH instructions for data-generating projects).

3) Prepare all registrations before manuscript time

Before you draft final forms:

• Complete organization registrations and confirm SAM status.
• Ensure each PD/PI has a usable eRA Commons profile with role consistency.
• Confirm Grants.gov access for the sponsoring account path.

NIH repeatedly notes that lack of registration completion is not a valid reason for late submission.

4) Produce compliant package by channel

For each allowed submission channel, verify you are using the exact forms expected by NIH and that every section has the required fields. The NOFO itself references page limits and instructions in the NIH Application Guide and points to required instructions in forms such as SF424(R&R), PHS 398 sections, human-subjects sections, and submission supplements. Deviations in form completion are a common failure mode.

5) Build internal deadline buffer

Submit early. NIH explicitly encourages early submission to fix validation errors and changed-corrected package corrections before due time. If a correction is submitted after the deadline, the application is late.

If the due date falls on a weekend or federal holiday, NIH states the effective date moves to next business day, but do not rely on that as a strategy.

Review logic and what reviewers usually focus on

The review section in the NOFO is where most strategic errors become clear. Reviewers evaluate the full package for scientific and technical merit and provide an overall impact score. The scored factors are:

1. Significance and Innovation
2. Approach (Rigor and Feasibility)
3. Investigator(s) and Environment

Focus 1: Clinical trial design clarity

The review language emphasizes rigor, reproducibility, feasibility, and whether the trial timeline and milestones are realistic. Even strong innovation language is weaker without a robust feasibility section that explains recruitment, retention, and analysis logic.

Focus 2: Biological or behavioral variables and representativeness

The NOFO wording calls for clear planning around sex, age, and relevant biological variables in design and reporting. For clinical trials, reviewers also inspect inclusion plans and whether target representation aligns with disease burden and population context.

Focus 3: Environment and leadership quality

Strong PI track record, matched team mix, and institutional infrastructure are scored through Factor 3. Multiple PI applications need a visible coordination plan.

Focus 4: Additional review dimensions

Reviewers may also evaluate:

• human subject protections,
• animal use plans (if applicable),
• biohazard controls,
• budget reasonableness,
• resource authentication.

Applications not meeting quality and compliance thresholds may still fail regardless of science strength.

Key admin requirements you should plan for now

Several requirements affect timeline and resource allocation:

• No paper submissions are allowed.
• Changed/Corrected submissions after due date are late.
• All applications undergo completeness checks by NIH systems.
• For requests of $500,000+ direct costs per year (excluding consortium F&A), NIH requires additional pre-submission scientific contact and policy steps.
• Post-award obligations include reporting and policy compliance (RPPR, PHS/clinical obligations, IRB updates).

The NOFO also notes clinical trial obligations such as registration/reporting where relevant.

For teams thinking “if funded, what next?”: build post-award capacity into your proposal. A clean post-submission record helps review confidence and award management readiness.

Common mistakes and how to avoid them

Mistake 1: Submitting non-clinical-trial work under this parent NOFO

This invalidates the mechanism fit. Confirm trial status in your aims and study design language before writing any specific aims.

Mistake 2: Incomplete PI or institutional registrations

SAM/eRA/Grants.gov gaps are avoidable but common. Start registration workflows in parallel with protocol writing.

Mistake 3: Weak clinical trial governance

Missing retention logic, incomplete risk/benefit framing, or vague inclusion strategy is a frequent reviewer weakness. Build concrete operational detail, not just scientific ambition.

Mistake 4: Copying a generic non-trial R01 narrative

The NOFO is strict about trials. If you reuse text from non-trial projects, reviewers and compliance checks will see the mismatch.

Mistake 5: Ignoring page limits and form instructions

NIH references the standard table and guide. Page and format violations can create correction churn or submission failure.

Mistake 6: Underestimating due-date cadence and overlap rules

Avoid parallel highly overlapping submissions across cycles. NIH policy can bar overlapping applications, and repeated retractions/resubmissions add dead-time.

Practical preparation timeline (90-day example)

T-minus 90 days

• Finalize trial question and feasibility scope.
• Confirm IC fit and contact IC scientific point of contact if needed.
• Start registrations and account audits.

T-minus 60 days

• Build detailed approach section with milestones and recruitment model.
• Prepare Data Management and Sharing Plan.
• Draft human subjects / trial sections and IRB assumptions.

T-minus 45 days

• Internal content audit against NIH page limits and forms.
• Prepare budget justification and year-by-year milestone alignment.
• Verify institutional signature and Commons roles.

T-minus 30 days

• First full package test in chosen system.
• Run pilot validation checks and fix all flagged compliance issues.
• Confirm resubmission policy path for major changes.

T-minus 10 days

• Final integrity pass and secondary-review by someone outside the grant-writing team.
• Confirm review-specific sections are internally coherent: significance, innovation, rigor, feasibility.

T-minus 2 days

• Final submission test and duplicate/overlap check.
• Keep a signed-off “go/no-go” checklist for compliance and attachments.

T-minus submission

• Submit early enough for correction windows.
• Track in eRA Commons and keep an eye on error status up to and past final upload.

FAQ (quick operational answers)

Is this opportunity still useful in 2026/2027?

Yes. The NOFO remains active with recurring cycles and an expiry date in 2028, so the 2026/2027 windows are currently relevant.

Is there a strict amount limit?

The NOFO states application budgets are not limited in a fixed NOFO max, but NIH expects budgets to be justified by project scope.

Does a foreign institution qualify?

Yes. The NOFO explicitly says non-domestic entities are eligible.

What is the minimum thing that must go in early?

Trial design logic, registration readiness, and IC alignment are the top three for this announcement.

Can institutions submit more than one application?

Yes, if applications are scientifically distinct; highly overlapping applications are restricted.

What usually differentiates strong applications?

Not one “perfect idea,” but strong execution design: measurable trial workflow, robust inclusion/recruitment, rigorous approach, and operational readiness.

Official links

• NIH NOFO (official source)
• NIH Guide for Grants and Contracts
• How to Apply - Application Guide
• Grants.gov
• eRA Commons
• SAM.gov

Final takeaway

If your project must be a clinical trial, this is the mechanism to anchor around. If your proposal is not a trial, this is the wrong path and often a strategic error.

Treat PA-25-305 as a structure first and then proofread it into rigor. The opportunity is broad and valuable, but broad opportunities are unforgiving on compliance details. Build a realistic trial execution model, align with the right IC, complete registrations early, and use an internal pre-submission audit checklist. That changes outcomes more than polishing prose at the end.